Universes collide: combining immunotherapy with targeted therapy for cancer
about
Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapyMelanoma: oncogenic drivers and the immune systemUnderstanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ TumorsThe association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIsIntegrated pathway and epistasis analysis reveals interactive effect of genetic variants at TERF1 and AFAP1L2 loci on melanoma risk.Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinomaDistinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors.CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.Integrating precision cancer medicine into healthcare-policy, practice, and research challenges.PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p.Melanoma Treatments: Advances and Mechanisms.Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination StudiesAfatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress.The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.Looking beyond the cancer cell for effective drug combinations.Classical and Targeted Anticancer Drugs: An Appraisal of Mechanisms of Multidrug Resistance.Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma.Improving patient outcomes to targeted therapies in melanoma.Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma.Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation.Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.First-line treatment of metastatic melanoma: role of nivolumab.Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
P2860
Q26769870-0D1FC17E-A64B-4EF1-9E6B-3F668BDA96EFQ26775598-CDBB0CF3-A707-4A20-923A-13602F97DBA8Q27691330-42731981-28AA-40DE-AE67-8DFCFF527929Q28553650-C7C8BC65-ED6F-49B0-9505-22F17F0F7860Q35987305-97B846BE-6296-437D-8266-335B9D30F056Q36051433-607B0461-333D-4DBE-91D6-AA70D8F39AF1Q36605917-51115673-F421-41BF-B648-451F7004D034Q36821164-2D318990-B85E-4DB7-AD3D-89E5B58655FFQ36917882-AB4D736F-453A-4400-9FB1-F61857776F0AQ37042256-E850163C-58D1-4906-AEBB-CB65E253529BQ37360550-8E4C5929-191C-4341-9669-508C958E9442Q37716640-79BDBD46-0C41-41E9-9F5B-2DBA81DAB2D4Q38433788-254D3D06-AC44-4AC0-A961-7A712DE702F1Q38641329-8A22CE32-32D8-465B-897D-EFF1DE2FA082Q38646686-7246407B-6F26-4153-97EF-DFFE909B89EAQ38718460-0D914A04-8CE2-4B3D-98E4-3C6879700B25Q38728970-E28D713C-FC93-4117-8A97-4C490FD7FEBAQ38748106-5194E40F-324E-4684-92EF-234F6B9717D5Q38753142-EB69D1AC-28C7-484F-AB2C-3CE7F90A686DQ38823508-02D9119C-E420-42F8-A92E-EC14FF6C36ACQ38839130-CB6E565D-ECD4-4417-8DE3-19A42ABA9105Q39043132-18CEC4A6-EC79-4A17-AF5F-9AEF6AB4D0DFQ39069585-83C9E5DC-7CD0-42F7-A58C-D5FC49A0586AQ39153808-FEC77B61-9A4D-4A4F-9344-9A06838A1133Q47143892-241B132F-0479-4B40-851A-81C775242B1BQ47350013-175B9F70-C3B0-4620-A6CD-23FB96B47089Q58547833-4C0B62AF-D638-43F3-AD1F-6BA7F2939EB2
P2860
Universes collide: combining immunotherapy with targeted therapy for cancer
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Universes collide: combining immunotherapy with targeted therapy for cancer
@ast
Universes collide: combining immunotherapy with targeted therapy for cancer
@en
Universes collide: combining immunotherapy with targeted therapy for cancer
@nl
type
label
Universes collide: combining immunotherapy with targeted therapy for cancer
@ast
Universes collide: combining immunotherapy with targeted therapy for cancer
@en
Universes collide: combining immunotherapy with targeted therapy for cancer
@nl
prefLabel
Universes collide: combining immunotherapy with targeted therapy for cancer
@ast
Universes collide: combining immunotherapy with targeted therapy for cancer
@en
Universes collide: combining immunotherapy with targeted therapy for cancer
@nl
P2860
P3181
P1433
P1476
Universes collide: combining immunotherapy with targeted therapy for cancer
@en
P2093
Jennifer A Wargo
Keith T Flaherty
P2860
P304
P3181
P356
10.1158/2159-8290.CD-14-0477
P407
P577
2014-11-13T00:00:00Z